surmount-1 tirzepatide weight loss nondiabetic Read now: The SURPASS-EARLY trial found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m SURMOUNT-3 study design This is

The risk of the primary outcome was 24% lower in all participants treated with semaglutide versus placebo (95% confidence interval: 34%, 12%)

Medicare members should also ask about the GLP-1 Bridge eligibility (launching July 1, 2026), which provides weight-loss access at $50 per month outside Part D

In recent years, diet-based approaches and nutritional supplementation have gained extensive attention for managing NAFLD/MASLD

Neuropeptide levels in Alzheimers disease and dementia with frontotemporal degeneration

This fluid lubricates the joint and provides nutrients to the cartilage, helping maintain its health and function

The TPMO framework streamlines the patient journey through three synergistic phases